<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32599739</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>MicroRNA-5572 Is a Novel MicroRNA-Regulating <i>SLC30A3</i> in Sporadic Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4482</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21124482</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease caused by the loss of motor neurons. Although the pathogenesis of sporadic ALS (sALS) remains unclear, it has recently been suggested that disorders of microRNA (miRNA) may be involved in neurodegenerative conditions. The purpose of this study was to investigate miRNA levels in sALS and the target genes of miRNA. Microarray and real-time RT-PCR analyses revealed significantly-decreased levels of miR-139-5p and significantly increased levels of miR-5572 in the spinal cords of sALS patients compared with those in controls. We then focused on miR-5572, which has not been reported in ALS, and determined its target gene. By using TargetScan, we predicted <i>SLC30A3</i> as the candidate target gene of miR-5572. In a previous study, we found decreased <i>SLC30A3</i> levels in the spinal cords of sALS patients. We revealed that <i>SLC30A3</i> was regulated by miR-5572. Taken together, these results demonstrate that the level of novel miRNA miR-5572 is increased in sALS and that <i>SLC30A3</i> is one of the target genes regulated by miR-5572.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurita</LastName><ForeName>Hisaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yabe</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inden</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, 1 Asahimachi, Chuo-ku, Niigata 951-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hozumi</LastName><ForeName>Isao</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0984-6291</Identifier><AffiliationInfo><Affiliation>Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi Gifu city, Gifu 501-1196, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>15K21278</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>17K18001</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>JP19H05767A02</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>2019-23</GrantID><Agency>the Collaborative Research Project of Brain Research Institute, Niigata University</Agency><Country/></Grant><Grant><GrantID>28-16</GrantID><Agency>Grant-in-Aid of The Nakabayashi Trust For ALS Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102806">SLC30A3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">microarray</Keyword><Keyword MajorTopicYN="N">spinal cord</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32599739</ArticleId><ArticleId IdType="pmc">PMC7350020</ArticleId><ArticleId IdType="doi">10.3390/ijms21124482</ArticleId><ArticleId IdType="pii">ijms21124482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozumi I., Hasegawa T., Honda A., Ozawa K., Hayashi Y., Hashimoto K., Yamada M., Koumura A., Sakurai T., Kimura A., et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J. Neurol. Sci. 2011;303:95&#x2013;99. doi: 10.1016/j.jns.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.01.003</ArticleId><ArticleId IdType="pubmed">21292280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M., Noguchi T., Ikegami S., Sakurai T., Kakita A., Toyoshima Y., Kambe T., Yamada M., Inden M., Hara H., et al. Zinc transporters ZnT3 and ZnT6 are downregulated in the spinal cords of patients with sporadic amyotrophic lateral sclerosis. J. Neurosci. Res. 2015;93:370&#x2013;379. doi: 10.1002/jnr.23491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23491</ArticleId><ArticleId IdType="pubmed">25284286</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Thomson A., Kurien C., Shytle R.D., Sanberg P.R. Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert. Rev. Neurother. 2016;16:1397&#x2013;1405. doi: 10.1080/14737175.2016.1207530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2016.1207530</ArticleId><ArticleId IdType="pmc">PMC5164916</ArticleId><ArticleId IdType="pubmed">27362330</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis N.J. What can we learn from the edaravone development program for ALS? Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:98&#x2013;103. doi: 10.1080/21678421.2017.1361446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361446</ArticleId><ArticleId IdType="pubmed">28872911</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil V.V., Katzman R.B., Petrucelli L. ALS and FTD: An epigenetic perspective. Acta Neuropathol. 2016;132:487&#x2013;502. doi: 10.1007/s00401-016-1587-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1587-4</ArticleId><ArticleId IdType="pmc">PMC5138862</ArticleId><ArticleId IdType="pubmed">27282474</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntzinger E., Izaurralde E. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat. Rev. Genet. 2011;12:99&#x2013;110. doi: 10.1038/nrg2936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2936</ArticleId><ArticleId IdType="pubmed">21245828</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak I., Patil K.S., Alves G., Larsen J.P., Moller S.G. microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. Cell. Mol. Life Sci. 2016;73:811&#x2013;827. doi: 10.1007/s00018-015-2093-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2093-x</ArticleId><ArticleId IdType="pubmed">26608596</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L., Yu J.T. Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. Mol. Neurobiol. 2015;51:1249&#x2013;1262. doi: 10.1007/s12035-014-8803-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8803-9</ArticleId><ArticleId IdType="pubmed">24973986</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja R., Regev K., Healy B.C., Mazzola M.A., Beynon V., von Glehn F., Paul A., Diaz-Cruz C., Gholipour T., Glanz B.I., et al. Correlating serum microRNAs and clinical parameters in Amyotrophic lateral sclerosis. Muscle Nerve. 2018;58:261&#x2013;269. doi: 10.1002/mus.26106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26106</ArticleId><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>De Andrade H.M., de Albuquerque M., Avansini S.H., de S.R.C., Dogini D.B., Nucci A., Carvalho B., Lopes-Cendes I., Franca M.C., Jr. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. 2016;368:19&#x2013;24. doi: 10.1016/j.jns.2016.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.046</ArticleId><ArticleId IdType="pubmed">27538595</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A.P., Wada S., Vergani L., Hock M.B., Lamon S., Leger B., Ushida T., Cartoni R., Wadley G.D., Hespel P., et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;49:107&#x2013;117. doi: 10.1016/j.nbd.2012.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.015</ArticleId><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen J.M., Manzano R., Olivan S., Zaragoza P., Garcia-Redondo A., Osta R. MicroRNA-206: A potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS ONE. 2014;9:e89065. doi: 10.1371/journal.pone.0089065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089065</ArticleId><ArticleId IdType="pmc">PMC3930686</ArticleId><ArticleId IdType="pubmed">24586506</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B., Annunziata A., Fiorentino G., Borra M., Biffali E., Coppola C., Cotrufo R., Brettschneider J., Giordana M.L., Dalmay T., et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243&#x2013;253. doi: 10.1007/s10048-014-0420-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0420-2</ArticleId><ArticleId IdType="pubmed">25130371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K., Mori F., Kakita A., Takahashi H., Utsumi J., Sasaki H. Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2014;2:173. doi: 10.1186/s40478-014-0173-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0173-z</ArticleId><ArticleId IdType="pmc">PMC4279903</ArticleId><ArticleId IdType="pubmed">25497327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G., Wang Y., Li Y., Cui L., Zhao Y., Zhao B., Li K. MiR-206, a key modulator of skeletal muscle development and disease. Int. J. Biol. Sci. 2015;11:345&#x2013;352. doi: 10.7150/ijbs.10921.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.10921</ArticleId><ArticleId IdType="pmc">PMC4323374</ArticleId><ArticleId IdType="pubmed">25678853</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonemori M., Seki N., Yoshino H., Matsushita R., Miyamoto K., Nakagawa M., Enokida H. Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 2016;107:1233&#x2013;1242. doi: 10.1111/cas.13002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13002</ArticleId><ArticleId IdType="pmc">PMC5021030</ArticleId><ArticleId IdType="pubmed">27355528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue S., Wang L., Zhang H., Min Y., Lou Y., Sun H., Jiang Y., Zhang W., Liang A., Guo Y., et al. miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 2015;36:6741&#x2013;6749. doi: 10.1007/s13277-015-3372-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-3372-8</ArticleId><ArticleId IdType="pubmed">25833697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita H., Okuda R., Yokoo K., Inden M., Hozumi I. Protective roles of SLC30A3 against endoplasmic reticulum stress via ERK1/2 activation. Biochem. Biophys. Res. Commun. 2016;479:853&#x2013;859. doi: 10.1016/j.bbrc.2016.09.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.09.119</ArticleId><ArticleId IdType="pubmed">27678294</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrushev N., Seidel-Rogol B., Salazar G. Angiotensin II requires zinc and downregulation of the zinc transporters ZnT3 and ZnT10 to induce senescence of vascular smooth muscle cells. PLoS ONE. 2012;7:e33211. doi: 10.1371/journal.pone.0033211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033211</ArticleId><ArticleId IdType="pmc">PMC3299759</ArticleId><ArticleId IdType="pubmed">22427991</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson C.L., Al-Chalabi A. Amyotrophic lateral sclerosis as a complex genetic disease. Biochim. Biophys. Acta. 2006;1762:973&#x2013;985. doi: 10.1016/j.bbadis.2006.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.08.001</ArticleId><ArticleId IdType="pubmed">16973338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>